ArticleFrontiers in psychiatry2025
An observational feasibility study on the impact of green exposure on major depressive episode symptomatology and inflammatory biomarkers.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Major depressive and bipolar disorders are prevalent mental health conditions sharing the presence of major depressive episodes (MDEs). While psychopharmacological and psychological therapies are first-line treatments for MDEs, the response is often incomplete. New approaches focused on the human-nature relationship might complement antidepressant treatments, improving response. Methods: This observational pilot study aims to assess the feasibility of implementing regular exposure to green environments such as woods, forests, large parks, and gardens for at least forty-five minutes twice a week in a sample of patients experiencing a MDE who require adjustments to their antidepressant therapy. It also has the purpose of detecting changes in symptoms and inflammatory biomarkers at follow-up after six weeks. Results: Fifty-three patients were evaluated at the baseline; thirty-one completed the study. Nineteen (61%) of the completers reported regular exposure to greenery during the study. At follow-up, actively exposed patients showed trends of improvements in depressive symptoms, lower levels of C-reactive protein and interleukin-6, and higher adiponectin concentrations. Discussion: This result suggests that incorporating green exposure into clinical practice is feasible and potentially useful. However, more rigorous evaluations on larger samples are needed to verify whether exposure to greenery may complement MDEs treatment and favorably impact MDE-associated inflammatory processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.